FrancophonIA/ELRC3.0 huggingface dataset:
English: Therefore, the CHMP's view was that, as for Glivec, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Gliveci korral, ületab ravimi Imatinib Teva kasulikkus sellega kaasnevad riskid.
English: Imatinib Teva contains the active substance imatinib.
Estonian: Imatinib Teva sisaldab toimeainena imatiniibi.
English: Because Imatinib Teva is a generic medicine, studies in patients have been limited to tests to determine that the tablets and capsules are bioequivalent to the reference medicine, Glivec.
Estonian: Et Imatinib Teva on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati tablettide ja kapslite bioekvivalentsust võrdlusravimiga Glivec.
English: It is not intended to provide practical advice on how to use Imatinib Teva.
Estonian: Hindamisaruandes ei anta Imatinib Teva kasutamise praktilisi nõuandeid.
English: This means that it blocks some specific enzymes known as tyrosine kinases.
Estonian: See tähendab, et toimeaine blokeerib teatud ensüümid türosiinkinaasid.
English: Imatinib Teva can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of patients with cancers of the blood.
Estonian: Imatinib Teva on retseptiravim ja ravi sellega peab alustama verevähiga patsientide ravis kogenud arst.
English: Imatinib Teva is used when the patients are ‘Philadelphia chromosome positive' (Ph+).
Estonian: Imatinib Tevat kasutatakse Philadelphia-kromosoom-positiivsetel (Ph+) patsientidel.
English: Imatinib Teva is a cancer medicine.
Estonian: Imatinib Teva on vähiravim.
English: For more information about treatment with Imatinib Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Imatinib Tevaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For practical information about using Imatinib Teva, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Imatinib Teva kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Other information about Imatinib Teva
Estonian: Muu teave Imatinib Teva kohta
English: • myelodysplastic or myeloproliferative diseases (MD/MPD), a group of diseases in which the body produces large numbers of abnormal blood cells.
Estonian: • Müelodüsplastilised või müeloproliferatiivsed haigused (MD/MPD) - haiguste rühm, mille korral organismis tekib suurel hulgal üht või mitut liiki ebanormaalseid vererakke.
English: Imatinib Teva is used in adults and children who have been newly diagnosed with Ph+ CML and who are not eligible for a bone marrow transplant.
Estonian: Imatinib Tevat kasutatakse täiskasvanutel ja lastel, kellel on äsja diagnoositud Philadelphia kromosoomiga krooniline müeloidleukeemia (Ph+ CML) ja kellele ei saa siirata luuüdi.
English: • advanced hypereosinophilic syndrome (HES) or chronic eosinophilic leukaemia (CEL), diseases in which eosinophils (another type of white blood cell) start growing out of control.
Estonian: • Edasiarenenud hüpereosinofiilia sündroom (HES) või krooniline eosinofiilne leukeemia (CEL)haigused, mille korral eosinofiilid (teatud leukotsüüdid) hakkavad takistamatult vohama.
English: This is a summary of the European public assessment report (EPAR) for Imatinib Teva.
Estonian: See on ravimi Imatinib Teva Euroopa avaliku hindamisaruande kokkuvõte.
English: Imatinib Teva is used to treat adults with DFSP that cannot be removed with surgery, and in adults who are not eligible for surgery when the cancer has returned after treatment or has spread to other parts of the body.
Estonian: Imatinib Tevat kasutatakse protuberantse dermatofibrosarkoomiga täiskasvanute raviks, kui sarkoomi ei saa kirurgiliselt eemaldada, kui kasvaja on pärast ravi taastunud või on siiretega (levinud organismis mujale).
English: • dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably.
Estonian: • Protuberantne dermatofibrosarkoom (DFSP) - vähiliik (sarkoom), mille korral nahaaluse koe rakud vohavad.
English: • Ph+ acute lymphoblastic leukaemia (ALL), a type of cancer in which lymphocytes (another type of white blood cell) multiply too quickly.
Estonian: • Philadelphia-kromosoom-positiivne akuutne lümfoblastne leukeemia (Ph+ ALL) - vähivorm, mille korral lümfotsüüdid (teatud leukotsüüdid) paljunevad liiga kiiresti.
English: Imatinib Teva is used to treat adults with HES or CEL who have a specific re-arrangement of two genes called FIP1L1 and PDGFRα;
Estonian: Imatinib Tevat kasutatakse kaugelearenenud hüpereosinofiilse sündroomi või kroonilise eosinofiilse leukeemiaga täiskasvanute ravimiseks, kellel on kaks geeni (FIP1L1 ja PDGFRα) teataval viisil muundunud.
English: How has Imatinib Teva been studied?
Estonian: Kuidas Imatinib Tevat uuriti?
English: Imatinib Teva is used to treat adults with MD/MPD who have re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR);
Estonian: Imatinib Tevat kasutatakse müelodüsplastiliste või müeloproliferatiivsete haigustega täiskasvanute ravimiseks, kellel on trombotsüütide kasvuteguri retseptori (PDGFR) geen muundunud.
English: How does Imatinib Teva work?
Estonian: Kuidas Imatinib Teva toimib?
English: What are the benefits and risks of Imatinib Teva?
Estonian: Milles seisneb Imatinib Teva kasulikkus ja mis riskid ravimiga kaasnevad?
English: Imatinib Teva is used in combination with other cancer medicines in adults and children who have been newly diagnosed with Ph+ ALL.
Estonian: Imatinib Tevat kasutatakse koos teiste vähiravimitega täiskasvanute ja laste raviks, kellel on äsja diagnoositud Philadelphiakromosoom-positiivne akuutne lümfoblastne leukeemia (Ph+ ALL).
English: How is Imatinib Teva used?
Estonian: Kuidas Imatinib Tevat kasutatakse?
English: The active substance in Imatinib Teva, imatinib, is a protein-tyrosine kinase inhibitor.
Estonian: Imatinib Teva toimeaine imatiniib on proteiintürosiinkinaasiinhibiitor.
English: • chronic myeloid leukaemia (CML), a cancer of the white blood cells in which granulocytes (a type of white blood cell) start growing out of control.
Estonian: See on leukotsüütide (vere valgeliblede) vähk, mille korral hakkavad granulotsüüdid (teatud leukotsüüdid) takistamatult vohama.
English: It is a ‘generic medicine'.
Estonian: Imatinib Teva on geneeriline ravim.
English: EU - Number Invented name
Estonian: EL number
English: This summary was last updated in 09-2012.
Estonian: Kokkuvõtte viimane uuendus: 09-2012.
English: The CHMP also noted that the risks of using the medicine are well known.
Estonian: Komitee märkis samuti, et ravimi kasutamise riskid on hästi teada.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Xaluprine on 9 March 2012.
Estonian: Euroopa Komisjon andis ravimi Xaluprine müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 9. märtsil 2012.
English: It can be taken with food (except dairy products) or on an empty stomach but this should be consistent from day to day.
Estonian: Ravimit tohib võtta koos toiduga (välja arvatud piimatooted) või tühja kõhuga, kuid iga päev ühtmoodi.
English: The effectiveness of 6-mercaptopurine in slowing down the progression of ALL is already well known since it has been used for many years.
Estonian: 6-merkaptopuriini efektiivsus ägeda lümfoblastleukeemia progresseerumise aeglustamisel on hästi teada, sest seda on kasutatud aastaid.
English: The dose is determined for each patient mainly by body surface area and may be adjusted according to its effects in the blood.
Estonian: Annus määratakse iga patsiendi jaoks peamiselt kehapindala järgi ja seda saab kohandada verele avalduva mõju alusel.
English: It must also not be used at the same time as patients are having a yellow fever vaccination.
Estonian: Samuti ei tohi ravimit kasutada ajal, kui patsiente vaktsineeritakse kollapalaviku vastu.
English: Because 6-mercaptopurine has been used for the treatment of ALL in the European Union for a number of years in the tablet form, the company presented results from the scientific literature of studies previously carried out with mercaptopurine tablets.
Estonian: Et 6-merkaptopuriini on tablettidena kasutatud Euroopa Liidus ägeda lümfoblastleukeemia raviks aastaid, esitas ettevõte merkaptopuriini tablettidega korraldatud varasemate uuringute tulemused teaduskirjandusest.
English: EPAR summary for the public mercaptopurine
Estonian: Kokkuvõte üldsusele merkaptopuriin
English: The medicine is taken by mouth, using the syringe provided in the pack, once per day in the evening.
Estonian: Ravimit võetakse suu kaudu üks kord päevas õhtul, kasutades pakendis olevat süstalt.
English: 6mercaptopurine prevents them from dividing and they eventually die, thereby slowing down the progression of the leukaemia.
Estonian: 6-merkaptopuriin pärsib nende jagunemist ja lõpuks lümfotsüüdid hävivad, aeglustades sellega leukeemia progresseerumist.
English: The bioavailability study compared the way the two different forms of the same medicine are absorbed in the human body and the levels of the active substance they produce.
Estonian: Biosaadavuse uuringus võrreldi, kuidas inimorganism omastab sama ravimi kaht eri ravimvormi ja mis toimeainesisalduse need tekitavad.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Xaluprine can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Estonian: Harvikravimite komitee arvamuse kokkuvõte ravimi Xaluprine kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
English: Xaluprine is a medicine that contains the active substance mercaptopurine.
Estonian: Xaluprine on ravim, mis sisaldab toimeainena merkaptopuriini.
English: The Committee considered that an oral suspension allows more accurate dosing and is more convenient for children unable to swallow tablets.
Estonian: Komitee leidis, et suukaudset suspensiooni saab annustada täpsemini ja see on mugavam lastele, kes ei suuda tablette neelata.
English: It is available as an oral suspension.
Estonian: Seda turustatakse suukaudse suspensioonina.
English: In ALL the lymphocytes multiply too quickly and live for too long.
Estonian: Ägeda lümfoblastleukeemia korral paljunevad lümfotsüüdid liiga kiiresti ja püsivad aktiivsetena liiga kaua.
English: The added benefit of Xaluprine is that, as an oral suspension, it will provide more accuracy in dosing and it is easier to be taken by children.
Estonian: Ravimi Xaluprine lisaeelised on, et suukaudse suspensioonina võimaldab täpsemat annustamist ja lastel on seda lihtsam võtta.
English: The full EPAR for Xaluprine can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Xaluprine kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The bioavailability study showed that Xaluprine is comparable to the tablets, but it works in a more predictable way and has a higher rate of absorption, for which reason the dose will need to be adjusted when a patient switches from one formulation to the other.
Estonian: Biosaadavuse uuring näitas, et ravim Xaluprine on võrreldav tablettidega, kuid toimib eelduspärasemal viisil ja imendumiskiirus on suurem, mille tõttu tuleb annust patsiendi üleminekul ühelt ravimvormilt teisele kohandada.
English: The Committee concluded that the benefits of Xaluprine are greater than its risks and recommended that it be granted marketing authorisation.
Estonian: Inimravimite komitee järeldas, et ravimi Xaluprine kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The most common side effects with mercaptopurine (seen in more than 1 patient in 10) are leucopenia (low white blood cell counts) and thrombocytopenia (low blood platelet counts).
Estonian: Merkaptopuriini kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on leukopeenia (leukotsüütide ehk vere valgeliblede vähesus) ja trombotsütopeenia (trombotsüütide ehk vereliistakute vähesus).
English: For more information about treatment with Xaluprine, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Xaluprine toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Because the number of patients with ALL is low, the disease is considered ‘rare', and Xaluprine was designated an ‘orphan medicine' (a medicine used in rare diseases) on 30 April 2009.
Estonian: Et ägeda lümfoblastleukeemiaga patsientide arv on väike ja see haigus esineb harva, nimetati Xaluprine 30. aprillil 2009 harvikravimiks.
English: Medicines containing mercaptopurine in tablet form have been already used in the EU for many years to treat patients with ALL.
Estonian: Merkaptopuriini sisaldavaid tablette on Euroopa Liidus kasutatud ägeda lümfoblastleukeemiaga patsientide raviks aastaid.
English: The CHMP noted that mercaptopurine is established as an important treatment for ALL and that the only authorised form in the EU is a 50 mg tablet, making it difficult to adjust the dose for smaller children.
Estonian: Inimravimite komitee märkis, et merkaptopuriin on oluline ägeda lümfoblastleukeemia ravim, kuid ainus ravimvorm, millel on Euroopa Liidus müügiluba, on 50 mg tablett, mis raskendab väikelaste annuse kohandamist.
English: Xaluprine must not be used in people who are hypersensitive (allergic) to mercaptopurine or any of the other ingredients.
Estonian: Ravimit Xaluprine ei tohi kasutada patsiendid, kes on merkaptopuriini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: The active substance in this medicine, mercaptopurine has a similar chemical structure to purine, which is one of the fundamental chemicals that make up DNA.
Estonian: Ravimi toimeaine merkaptopuriin sarnaneb keemilise struktuuri poolest puriiniga, mis on üks peamisi aineid, millest tekib DNA.
English: Xaluprine is used to treat children, adolescents and adults who have acute lymphoblastic leukaemia (ALL), a cancer of the lymphocytes (a type of white blood cell).
Estonian: Ravimit Xaluprine kasutatakse laste, noorukite ja täiskasvanute raviks, kellel on äge lümfoblastiline leukeemia (ALL, lümfotsüütide ehk vere teatud valgeliblede vähiliik).
English: This is a summary of the European public assessment report (EPAR) for Xaluprine.
Estonian: See on ravimi Xaluprine Euroopa avaliku hindamisaruande kokkuvõte.
English: Other information about Xaluprine
Estonian: Muu teave ravimi Xaluprine kohta
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xaluprine.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: A study was also carried out to compare the bioavailability of Xaluprine, which is an oral suspension, with that of the tablet.
Estonian: Samuti korraldati uuring, kus võrreldi ravimi Xaluprinee suukaudse suspensiooni biosaadavust tablettide omaga.
English: Treatment with this medicine should be supervised by a healthcare professional experienced in treating patients with ALL.
Estonian: Ravi selle ravimiga peab toimuma ägeda lümfoblastleukeemia ravis kogenud arsti järelevalve all.
English: In the body, 6-mercaptopurine is converted within cells into a substance that interferes with the production of new DNA.
Estonian: Organismis muutub 6-merkaptopuriin rakkudes aineks, mis takistab uue DNA tekkimist, mis omakorda pärsib rakkude jagunemist.
English: What is the risk associated with Xaluprine?
Estonian: Mis riskid ravimiga Xaluprine kaasnevad?
English: Why has Xaluprine been approved?
Estonian: Miks ravim Xaluprine heaks kiideti?
English: For more information, see the summary of product characteristics (also part of the EPAR).
Estonian: Üksikasjalik teave on ravimi omaduste kokkuvõttes, mis on samuti Euroopa avaliku hindamisaruande osa.
English: How has Xaluprine been studied?
Estonian: Kuidas ravimit Xaluprine uuriti?
English: How is Xaluprine used?
Estonian: Kuidas ravimit Xaluprine kasutatakse?
English: What is Xaluprine?
Estonian: Mis on ravim Xaluprine?
English: What is Xaluprine used for?
Estonian: Milleks ravimit Xaluprine kasutatakse?
English: How does Xaluprine work?
Estonian: Kuidas ravim Xaluprine toimib?
English: What benefit has Xaluprine shown during the studies?
Estonian: Milles seisneb uuringute põhjal ravimi Xaluprine kasulikkus?
English: For the full list of all side effects, see the package leaflet.
Estonian: Ravimi Xaluprine kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: • you are pregnant.
Estonian: • kui olete rase.
English: Therefore, use in these patients should be avoided.
Estonian: Seetõttu tuleb kasutamist nendel patsientidel vältida.
English: Safety and efficacy were maintained throughout all cycles.
Estonian: Ohutus ja efektiivsus püsisid kõikide tsüklite vältel.
English: The effects were reversible or partially reversible after the recovery period.
Estonian: Toime oli pöörduv või pärast taastumisperioodi osaliselt pöörduv.
English: If this happens, do not drive or use any tools or machines.
Estonian: Sel juhul ärge juhtige autot ega kasutage tööriistu või masinaid.
English: Date of first authorisation: 27 May 2015 Date of latest renewal:
Estonian: Müügiloa esmase väljastamise kuupäev: 27. mai 2015 Müügiloa viimase uuendamise kuupäev:
English: These effects were not considered clinically important.
Estonian: Neid toimeid ei peetud kliiniliselt oluliseks.
English: Akynzeo contains two medicines (‘active substances') called:
Estonian: Akynzeo sisaldab kahte ravimit (toimeainet), milleks on:
English: Elimination via both routes was estimated to be complete by Day 29-30 post-dose.
Estonian: Eritumine kummagi tee kaudu on hinnanguliselt lõppenud 29.-30. päeval pärast annustamist.
English: Absolute netupitant bioavailability data are not available in humans; based on data from two studies with intravenous netupitant, the bioavailability in humans is estimated to be greater than 60%.
Estonian: Netupitandi absoluutse biosaadavuse andmed inimeste kohta puuduvad; kahest intravenoosse netupitandiga läbi viidud uuringust pärinevate andmete põhjal on biosaadavus inimestel hinnanguliselt suurem kui 60%.
English: Dialysis studies have not been performed.
Estonian: Dialüüsi uuringuid ei ole läbi viidud.
English: Akynzeo should not be taken by children and adolescents under 18 years.
Estonian: Akynzeod ei tohi võtta lapsed ja alla 18-aastased noorukid.
English: • chest pain (not related to the heart)
Estonian: • valu rindkeres (ei ole seotud südamega);
English: No antiemetic treatment
Estonian: Ilma antiemeetilise ravita
English: The usual dose is 1 capsule.
Estonian: Tavaline annus on 1 kapsel.
English: You may feel dizzy or tired after taking Akynzeo.
Estonian: Võite pärast Akynzeo võtmist tunda peapööritust või väsimust.
English: • Do not use this medicine after the expiry date which is stated on the carton and blister after ‘EXP'.
Estonian: • Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud karbil ja blisterpakendil pärast tähist „Kõlblik kuni/EXP”.
English: Approximately 62% of palonosetron is bound to plasma proteins.
Estonian: Ligikaudu 62% palonosetroonist seondub plasmavalkudega.
English: Plasma concentrations followed a first order absorption process and reached Cmax in approximately 5 hours.
Estonian: Plasmakontsentratsioonid läbisid esimese järgu imendumisprotsessi ja Cmax saavutati ligikaudu 5 tunniga.
English: • Take the capsule about 1 hour before you start your chemotherapy cycle.
Estonian: • Võtke kapsel ligikaudu 1 tund enne kemoteraapia tsükli algust.
English: Days 2 to 3
Estonian: 2. kuni 3. päev
English: Adverse reactions are listed below by MedDRA body system organ class and frequency.
Estonian: Allpool on MedDRA organsüsteemi klasside ja esinemissageduse alusel loetletud kõrvaltoimed.
English: (shown in blood tests)
Estonian: (avaldub vereanalüüsides);
English: • The active substances are palonosetron and netupitant.
Estonian: • Toimeained on palonosetroon ja netupitant.
English: After completion of cycle 1, patients had the option to participate in a multiple-cycle extension, receiving the same treatment as assigned in cycle 1.
Estonian: Pärast 1. tsükli lõppu anti patsientidele võimalus osaleda mitmetsüklilises jätkuosas, milles kasutati 1. tsüklis määratud ravi.
English: The impact of nausea and vomiting on patients' daily lives was assessed using the Functional Living Index-Emesis (FLIE).
Estonian: Iivelduse ja oksendamise mõju patsientide igapäevaelule hinnati oksendamist käsitleva funktsionaalse eluindeksi (Functional Living Index - Emesis, FLIE) abil.
English: The significance of these findings in humans is unknown.
Estonian: Nende leidude olulisus inimestel ei ole teada.
English: A summary of the key results from this study is shown in Table 3 below.
Estonian: Selle uuringu põhitulemuste kokkuvõte on toodud alljärgnevas tabelis 3.
English: Days 2 to 4
Estonian: 2. kuni 4. päev
English: Patients continued into the Multiple-Cycle extension for up to 7 additional cycles of chemotherapy.
Estonian: Patsiendid osalesid mitmetsüklilises jätkuosas kuni 7 kemoteraapia edasise tsükli vältel.
English: The clinical relevance of this effect is not established.
Estonian: Selle toime kliinilist asjakohasust ei ole kindlaks määratud.
English: Of these, 1438 patients (98.8%) completed cycle 1 and 1286 patients (88.4%) continued treatment in the multiple-cycle extension.
Estonian: Nendest patsientidest lõpetas 1. tsükli 1438 patsienti (98,8%) ja 1286 patsienti (88,4%) jätkas ravi mitmetsüklilises jätkuosas.
English: Since it may induce dizziness, somnolence or fatigue, patients should be cautioned not to drive or use machines if such symptoms occur.
Estonian: Kuna ravim võib põhjustada pearinglust, unisust või väsimust, tuleb patsiente hoiatada, et nad ei juhiks autot ega käsitseks masinaid, kui tekivad sellised sümptomid.
English: If you are allergic to peanut or soya, see your doctor straight away if you notice any signs of an allergic reaction.
Estonian: Kui olete maapähkli või soja suhtes allergiline, pöörduge viivitamatult oma arsti poole, kui täheldate allergilise reaktsiooni nähte.
English: In case of overdose, the medicinal product should be discontinued and general supportive treatment and monitoring should be provided.
Estonian: Üleannustamise korral tuleb ravimi kasutamine katkestada, patsient peab saama üldist toetavat ravi ja teda tuleb jälgida.
English: One 300 mg/0.5 mg capsule should be administered approximately one hour prior to the start of each chemotherapy cycle.
Estonian: Üks 300 mg/0,5 mg kapsel manustatakse ligikaudu üks tund enne kemoteraapia iga tsükli algust.
English: * p-value from Cochran-Mantel-Haenszel test, stratified by age class and region.
Estonian: * p-väärtus Cochrani-Manteli-Haenszeli testist, stratifitseeritud vanuserühma ja regiooni alusel.
English: Post-marketing data indicates that the adverse reactions profile is generally similar to that seen in clinical trials.
Estonian: Turuletulekujärgsete andmete kohaselt on kõrvaltoimete profiil üldiselt sarnane kliinilistes uuringutes täheldatud profiiliga.
English: The third major metabolite, M2, is > 97% bound to plasma proteins.
Estonian: Kolmas oluline metaboliit M2 seondub > 97% ulatuses plasmavalkudega.
English: Other medicines and Akynzeo
Estonian: Muud ravimid ja Akynzeo